Coloplast A/S - Trading in Coloplast shares by board members, executives or associated persons

Interim financial results, H1 2024/25 1 October 2024 - 31 March 2025 Coloplast delivered 6% organic growth in Q2, impacted by the product recall in Interventional Urology and a softer quarter in...

Coloplast CEO Kristian Villumsen steps down from his CEO position as of today. The Board of Directors has asked Lars Rasmussen to step in as interim CEO. As the company is entering into a new...